Durvalumab Combined With S-1 as Adjuvant Therapy of Resectable BTC
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-12-30
Target enrollment:
Participant gender:
Summary
The aim of this study is to assess the efficacy and safety of durvalumab combined with S-1 as adjuvant therapy of resectable Biliary Tract Cancer(BTC) with high risk of recurrence
Phase:
PHASE2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences